HPV-Positive Oropharyngeal Cancer Retains a Strong Survival Advantage After Surgery in Patients Aged ≥70
Highlight
• In a retrospective, multicenter cohort of 345 patients aged ≥70 undergoing primary surgery for squamous cell carcinoma (SCC) of the tonsil or base of tongue (BOT), p16 positivity (a surrogate for HPV-associated disease) was associated with a 5‑year overall survival (OS) of 71.4% versus 47.7% for p16‑negative tumors (absolute difference 23.7%; adjusted HR for OS 0.36).
• Disease‑free survival (DFS) benefits paralleled OS: 5‑year DFS 66.4% for p16‑positive versus 40.8% for p16‑negative tumors (absolute difference 25.6%; adjusted HR for DFS 0.42).
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.